Cogent Biosciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Cogent Biosciences generated cash of -$153,624,000, which is less than the previous year. Cash used in financing activities reached the amount of $163,536,000 last year. Net change in cash is therefore -$87,912,000.
Cash Flow
| 2015 | 17.71M | -3.24M | 70.75M |
|---|---|---|---|
| 2016 | -18.64M | -30.42M | -40K |
| 2017 | -25.83M | 13.51M | -729K |
| 2018 | -32.48M | -10.53M | 70.34M |
| 2019 | -41.51M | 23.15M | 108K |
| 2020 | -35.85M | 8.42M | 232.19M |
| 2021 | -58.76M | -1.71M | 37.97M |
| 2022 | -118.63M | -124.71M | 163.55M |
| 2023 | -153.62M | -97.82M | 163.53M |
COGT Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 141.14M | 220.93M | 243.44M | 38.67M | 56.92M | 29.6M | 41.32M | 90.43M | 5.21M |
Operating activities | |||||||||
Net income | -192.41M | -140.24M | -72.27M | -74.80M | -31.83M | -34.53M | -25.49M | -18.12M | -6.59M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 3.58M | 5.87M | 147K | 720K | 1.29M | 1.32M | 1.17M | 830K | 179K |
Stock-based compensation expense | 30.62M | 18.36M | 11.68M | 6.01M | 3.24M | 0 | 1.34M | 1.01M | 248K |
| Deferred income tax benefit | 30.62M | 18.36M | 11.68M | 6.01M | 3.24M | 0 | 1.34M | 1.01M | 248K |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 0 | 0 | 0 | 2M | -332K | -838K | 98K | -634K | -294K |
Inventories | 0 | 0 | 0 | -3.55M | 1.21M | 2.21M | 931K | 784K | 220K |
Accounts payable | 4.81M | 2.35M | 2.75M | -2.45M | 1.66M | 367K | -31K | 389K | 705K |
Cash generated by operating activities | -153.62M | -118.63M | -58.76M | -35.85M | -41.51M | -32.48M | -25.83M | -18.64M | 17.71M |
Investing activities | |||||||||
Purchases Of Investments | -348.80M | -177.85M | 0 | 0 | -204K | -47.68M | -6.5M | -55.17M | 0 |
Investments In Property Plant And Equipment | -2.79M | -6.86M | -1.71M | 0 | -33K | -549K | -912K | -3.30M | -1.99M |
Acquisitions Net | 0 | 117.85K | 0 | 8.42M | 204K | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -97.82M | -124.71M | -1.71M | 8.42M | 23.15M | -10.53M | 13.51M | -30.42M | -3.24M |
Financing activities | |||||||||
Common Stock Issued | 161.81M | 161.94M | 38.00M | 132.72M | 108K | 71.79M | 60K | 0 | 70.75M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 163.53M | 163.55M | 37.97M | 232.19M | 108K | 70.34M | -729K | -40K | 70.75M |
Net Change In Cash | -87.91M | -79.79M | -22.50M | 204.76M | -18.24M | 27.32M | -13.05M | -49.10M | 85.21M |
Cash at end of period | 53.22M | 141.14M | 220.93M | 243.44M | 38.67M | 56.92M | 28.27M | 41.32M | 90.43M |
| Data source | Data source | Data source | Data source | Data source | Data source |